loading
Schlusskurs vom Vortag:
$5.76
Offen:
$5.75
24-Stunden-Volumen:
1.49M
Relative Volume:
0.58
Marktkapitalisierung:
$424.44M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-2.1988
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
+19.77%
1M Leistung:
+9.67%
6M Leistung:
-3.62%
1J Leistung:
-7.06%
1-Tages-Spanne:
Value
$5.66
$6.0996
1-Wochen-Bereich:
Value
$4.78
$6.0996
52-Wochen-Spanne:
Value
$2.8647
$9.305

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
Firmenname
Verve Therapeutics Inc
Name
Telefon
(978) 501-3026
Name
Adresse
201 BROOKLINE AVENUE, BOSTON
Name
Mitarbeiter
274
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
VERV's Discussions on Twitter

Vergleichen Sie VERV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VERV
Verve Therapeutics Inc
5.695 424.44M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.44 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.09 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.28 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.55 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
251.15 24.70B 3.81B -644.79M -669.77M -6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-04-08 Eingeleitet H.C. Wainwright Buy
2023-04-13 Eingeleitet Canaccord Genuity Buy
2023-02-01 Eingeleitet Cantor Fitzgerald Neutral
2022-12-15 Eingeleitet Goldman Sell
2022-10-06 Eingeleitet Credit Suisse Neutral
2022-08-25 Hochstufung Stifel Hold → Buy
2022-06-17 Eingeleitet BMO Capital Markets Outperform
2022-02-18 Eingeleitet RBC Capital Mkts Outperform
2021-09-24 Eingeleitet Stifel Hold
2021-07-12 Eingeleitet Guggenheim Buy
2021-07-12 Eingeleitet JP Morgan Neutral
2021-07-12 Eingeleitet Jefferies Buy
2021-07-12 Eingeleitet William Blair Outperform
Alle ansehen

Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten

pulisher
05:48 AM

Press Release Distribution & PR Platform - ACCESS Newswire

05:48 AM
pulisher
Apr 21, 2025

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga

Apr 21, 2025
pulisher
Apr 18, 2025

Why Verve Therapeutics Zoomed 40% Higher This Week - MSN

Apr 18, 2025
pulisher
Apr 16, 2025

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN

Apr 16, 2025
pulisher
Apr 15, 2025

Verve impresses investors with second shot at PCSK9 - BioCentury

Apr 15, 2025
pulisher
Apr 15, 2025

Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail

Apr 15, 2025
pulisher
Apr 15, 2025

Guggenheim raises Verve Therapeutics stock target to $24 By Investing.com - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com

Apr 15, 2025
pulisher
Apr 15, 2025

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Guggenheim Boosts Price Target for Verve Therapeutics (VERV) to $24 | VERV Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results - insights.citeline.com

Apr 14, 2025
pulisher
Apr 14, 2025

Early stage cardio data from Verve bump the stock - BioWorld MedTech

Apr 14, 2025
pulisher
Apr 14, 2025

Assessing Verve Therapeutics: Insights From 4 Financial Analysts - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. - Barron's

Apr 14, 2025
pulisher
Apr 14, 2025

Verve shares soar after new gene-editing trial shows no safety concerns - The Boston Globe

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics: FDA Nod Sparks Stock Surge - timothysykes.com

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics: A New Era in Cardiovascular Disease Treatment? - RagingBull

Apr 14, 2025
pulisher
Apr 14, 2025

Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns - Bloomberg.com

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Stock Rise: Is It A Turning Point? - timothysykes.com

Apr 14, 2025
pulisher
Apr 14, 2025

Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics reports promising trial results for cholesterol drug By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics reports promising trial results for cholesterol drug - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics stock soars on positive clinical trial results By Investing.com - Investing.com Nigeria

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - Yahoo

Apr 14, 2025
pulisher
Apr 11, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - ACCESS Newswire

Apr 11, 2025
pulisher
Apr 11, 2025

Verve stock gains on FDA fast track tag (VERV:NASDAQ) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102 - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9 - MarketScreener

Apr 11, 2025

Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Kapitalisierung:     |  Volumen (24h):